Simple Summary The lung cancer treatment paradigm has been completely changed by
immunotherapy; however, less than half of the treated patients obtain a response, and an …

Background In recent years, immune checkpoint inhibitor (ICI) therapy has greatly changed
the treatment prospects of patients with non-small cell lung cancer (NSCLC). Among the …

Simple Summary Lung cancer remains a leading cause of cancer-related mortality globally,
requiring new diagnostic and therapeutic approaches. This research arises from the need to …

Simple Summary Lung cancer is the leading cause of cancer death worldwide. Most lung
cancers are classified as non-small cell lung cancer (NSCLC), which is diagnosed at an …

Purpose To report two cases of hepatic cavernous hemangioma, a rare complication, in
patients with locally advanced and advanced non-squamous non-small cell lung cancer …

Background Immunotherapy represented a turning point for treating extensive small-cell
lung cancer (ES-SCLC). Although, many issues remain debated. Methods A group of Italian …

背景与目的近年来, 程序性细胞死亡受体1 (programmed cell death 1, PD-
1)/程序性细胞死亡配体1 (programmed cell death ligand 1, PD-L1) 免疫抑制剂为代表的免疫 …

Abstract Treatment challenges persist in advanced lung cancer despite the development of
therapies beyond the traditional platinum-based chemotherapy. The early 2000s marked a …

The treatment metastatic non-small cell lung cancer (NSCLC) is largely influenced by the
incorporation of immune checkpoint inhibitors (ICI) in the frontline setting. There are several …

Background: Driver mutations and immunological expressions have gained importance in
recent years for targeted therapies and immunotherapies of nonsmall cell lung cancer …